A substantial reduction in the amount and quality of collagen leads to age-related deterioration of the elasticity and firmness of the skin. In recent years, multiple compounds have been developed aimed at reversing the molecular features of dermal aging. One such target for aging reversal is collagen degradation or turnover. SA1-III is a decapeptide (Ac-Met-Gly-Lys-Val-Val-Asn-Pro-Thr-Gln-Lys-NH2), also known as KP1, formally derived from the C-terminal portion of serpin A1, an agent known as a physiological inhibitor of neutrophil elastase, and has been the subject of laboratory and clinical studies determining its effects on modulation of collagen turnover as well as the treatment of age-associated changes of the face. This review aims to provide a bio-inspired approach focusing on the latest scientific studies that describe the compound, as well as a comprehensive appraisal of laboratory and clinical tests on skincare formulations enriched with sA1-III.
BACKGROUND: Hyaluronic acid-based filler injections with parenteral anesthetics have become the standard in treating midface volume deficits. There are currently limited data on the effects of these types of fillers on skin density, thickness, and firmness. OBJECTIVE: This study aimed to assess the efficacy of XTRCL filler in improving skin quality and tissue volume in women with midface volume loss. MATERIALS AND METHODS: In this prospective, noncomparative, single-center study, 50 women aged between 40 and 60 years with midface volume loss were recruited. The primary endpoint was the improvement in investigator-assessed Global Aesthetic Improvement Scores (GAIS) 1 month after treatment. Secondary endpoints include objective measurements of skin density, thickness, and quality measurements, facial and/or cheek volume augmentation, subjective GAIS, and device evaluation from after the first injection until 6 months, and the documentation of injection site reactions and adverse events. RESULTS: XTRCL use led to significant improvement in midface volume deficits, and skin quality and skin thickness. Injector and subject satisfaction with the treatment were documented and only mild-to-moderate adverse reactions were reported. CONCLUSION: XTRCL was shown to be effective in improving volume loss and skin quality at 6 months.
14 November 2024 in International Journal of Women's Dermatology
Background: Hand rejuvenation with hyaluronic acid filler injections is gaining more attention for its ability to correct volume loss and improve skin quality. The hand dorsum is prone to loss of dermal elasticity and subcutaneous atrophy as individuals age, and administering hyaluronic acid fillers has become an option to restore the smoothness and youthful contour of the hand. Objective: The aim of this study is to demonstrate that injections with Definisse Touch Filler Plus Lidocaine are effective and safe for hand rejuvenation. Methods: Ten subjects underwent filler placement of 0.5 to 1.0 mL in the dorsal superficial lamina, which is devoid of sensory nerves and major skin vessels, using a blunt cannula via the fanning technique. Measurements were done before, immediately after, and 1 month after the treatment using validated aesthetic scales. Results: There was a significant correction of volume loss immediately after the first treatment and an improvement in skin texture and topography 1 month after the procedure. No lasting or severe adverse effects were observed. Limitations: To show significant and conclusive results, it is recommended to conduct further prospective, comparative, blinded studies in more subjects followed for longer periods (ie, 12 months or more). Objective analysis of volumetric changes using automated three-dimensional surface techniques is likewise beneficial. Conclusion: Injecting a low G-prime hyaluronic acid along the dorsal superficial lamina via cannula provides an effective and tolerable option for improving the appearance of aged hands.